From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Coherus BioSciences has announced promising results from its ongoing Phase 1 clinical trial of CHS-114, a selective anti-CCR8 antibody, in combination with toripalimab for patients with recurrent ...

an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this Treg depleting anti-CCR8 ...